BioBiz Buzz
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
Episodes
13 episodes
13. Tackling the undruggable: How Beactica's protein degradation platform might transform glioblastoma treatment
Targeted protein degradation (TPD) represents one of the most transformative advances in drug discovery, with the global market projected to expand from USD 641 million in 2025 to as much as USD 9.85 billion by 2035. This rapidly ev...
•
Season 1
•
Episode 13
•
31:51
12. Revolution technology set to transform breast cancer diagnosis and treatment.
Breast cancer affects women of all ages after puberty in every country. In 2022, the disease struck an estimated 2.3 million women and claimed 670 000 lives globally, according to the World Health Organization. The Global Breast Cancer Initiati...
•
Season 1
•
Episode 12
•
19:54
11. A technological breakthrough in the diagnosis of skin cancer
AI-based software solutions are increasingly being used as a second pair of eyes to help clinicians with the early diagnosis of diseases. With skin cancer seeing increasing rates of incidence and mortality, software solutions hold the key to he...
•
Season 1
•
Episode 11
•
26:14
10. How Bioxodes is using tick saliva to create an ICH stroke treatment breakthrough
In a disease where hope has been scarce for decades, Belgian biotech Bioxodes is rewriting the rules of stroke treatment. Join your host Mike Ward in conversation with CEO Marc Dechamps as he reveals how his team transformed an unlikely discove...
•
Season 1
•
Episode 10
•
26:26
9. Beyond Billion-Dollar Bets: How Affibody Might Solve Radioligand Therapy's Greatest Challenges
The radioligand therapy market will be worth $42 billion by 2032. However, beneath the headline-grabbing acquisitions lies a complex web of technical and commercial challenges that threaten to limit patient access to these revolutionary cancer ...
•
Season 1
•
Episode 9
•
26:33
8. Revolutionizing Cancer Drug Development with AI: How BioCopy is Using Physics to Rewrite the Rules of Biotech
By 2040, the World Health Organization predicts that one in two people will be diagnosed with cancer in their lifetime. Yet the traditional pharmaceutical industry remains trapped in a devastating cycle: developing next-generation cancer drugs ...
•
Season 1
•
Episode 8
•
19:40
7. Exploring new possibilities in reproductive medicine
ReproNovo demonstrated continued investor interest in the area of reproductive medicine by closing a $65 million Series A round earlier this year. In this episode, ReproNovo’s CEO and co-founder Jean Duvall joins your host, Cormac Sheridan, to ...
•
Season 1
•
Episode 7
•
28:24
6. Device Intelligence: How AI and Data Are Powering MedTech’s Next Frontier
In this episode of BioBiz Buzz, your host Shani Alexander is joined by Werner Lanthaler, founder and CEO of WLan Holding, to chart the seismic transformation underway in medical technology. Discover how the convergence of multi-omic diagnostics...
•
Season 1
•
Episode 6
•
29:44
5. Breaking New Ground in Pain Management with Non-Addictive Opioid Alternatives
As the opioid crisis continues to devastate communities worldwide, millions suffering from chronic and neuropathic pain face a critical dilemma: enduring debilitating pain or risking addiction with traditional opioid medications. In this episod...
•
Season 1
•
Episode 5
•
21:18
4. The Power of International Alliances: Unpacking the Swiss Biotech Report 2025
In 2024, despite a challenging global financial climate, Switzerland’s biotech sector showed remarkable resilience, maintaining steady revenues of CHF 7.2 billion while achieving a 22% increase in capital investment.In this episode of Bi...
•
Season 1
•
Episode 4
•
26:01
3. Rewriting the Future of Rare Cardiovascular Disease Through Epigenetic Innovation
In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pulmonary disease therapeutics. Cer...
•
Season 1
•
Episode 3
•
23:29
2. Breaking Barriers in Sexual Health: Dicot Pharma’s LIB-01 and the Future of ED Treatment
This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide. Your host Mike Ward interviews Elin Trampe,...
•
Season 1
•
Episode 2
•
14:23
1. CRISPR Unleashed: How Caszyme Is Redefining the Future of Gene Editing
This episode of BioBiz Buzz features Dr. Monika Paule, CEO and co-founder of Caszyme, a pioneering Lithuanian biotech company at the forefront of CRISPR-Cas technology. Your host Mike Ward explores how Caszyme is expanding the bound...
•
Season 1
•
Episode 1
•
19:54
